Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein.
<h4>Unlabelled</h4>The objectives of this non-randomized, non-blinded, dose-escalating Phase I clinical trial were to assess the safety, reactogenicity and immunogenicity of ICC-1132 formulated with Alhydrogel (aluminum hydroxide) in 51 healthy, malaria-naive adults aged 18 to 45 years....
Saved in:
| Main Authors: | Aric L Gregson, Giane Oliveira, Caroline Othoro, J Mauricio Calvo-Calle, George B Thorton, Elizabeth Nardin, Robert Edelman |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2008-02-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0001556&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Variation in the circumsporozoite protein of Plasmodium falciparum: vaccine development implications.
by: Kavita Gandhi, et al.
Published: (2014-01-01) -
Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein.
by: Lawrence T Wang, et al.
Published: (2021-12-01) -
A sting in the tail—are antibodies against the C‐terminus of Plasmodium falciparum circumsporozoite protein protective?
by: Jem Murdoch, et al.
Published: (2023-04-01) -
Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults.
by: Ruth D Ellis, et al.
Published: (2010-01-01) -
WORLDWIDE GENETIC POLYMORPHISM OF CIRCUMSPOROZOITE PROTEIN IN PLASMODIUM VIVAX SEQUENCES: A SYSTEMATIC REVIEW
by: Marrara Pereira Sampaio, et al.
Published: (2024-11-01)